|By Marketwired .||
|July 9, 2014 11:24 AM EDT||
COLUMBIA, MD and TORONTO, ON -- (Marketwired) -- 07/09/14 -- Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
The Title of the patent is "Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products." The author of this patent is John Mon, COO for Medifocus. John Mon stated, "This patent, along with the other recently issued patents, allows Medifocus to partner up with other bio-tech companies in helping to develop and commercialize targeted thermoactivated/released drugs and gene products which, in our opinion, is the future of medicine."
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the proposed transactions and neither of the foregoing entities has approved or disapproved of the contents of this press release.
About Medifocus, Inc.
Medifocus develops and commercializes minimally invasive, unique focused heat treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, or Benign Prostatic Hyperplasia ("BPH").
The Company owns two technology platforms with comprehensive US and international patent protection: The "Endo-thermotherapy Platform" and the "Adaptive Phased Array Microwave Focusing Platform". Based on these platform technologies, the Company has developed two advanced therapeutic products: the Prolieve® system for the treatment of BPH, and the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer.
The U.S. FDA-approved Prolieve® System (www.prolieve.com) is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The heating plus dilatation treatment offered by the Prolieve® System is the only minimally invasive treatment which offers both immediate and long term relief of symptoms due to enlarged prostate (BPH) in men. The clinical indication received for Prolieve from the FDA is an "alternative to drug therapy." With this indication, the Prolieve® System is a revenue generating device based product which can have the potential of catering to the $8 billion non-surgical prescription drug therapy market for treatment of BPH.
The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete, and has now begun the APA 1000's pivotal Phase-III clinical trials. Successful completion of the phase III trial will lead to commercial approval (PMA) of the product.
The Company is currently focusing on increasing revenue from the Prolieve® system for the treatment of BPH and completing the APA 1000 breast cancer system's Phase III study. For more information, visit www.medifocusinc.com.
Forward-Looking Statements and Information: This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
For further information about the Company:
Chief Operating Officer
Telephone (410) 290-5734
Jul. 24, 2016 09:00 AM EDT Reads: 771
Jul. 24, 2016 09:00 AM EDT Reads: 1,498
Jul. 24, 2016 08:45 AM EDT Reads: 866
Jul. 24, 2016 08:30 AM EDT Reads: 1,456
Jul. 24, 2016 08:30 AM EDT Reads: 2,048
Jul. 24, 2016 08:15 AM EDT Reads: 1,808
Jul. 24, 2016 08:15 AM EDT Reads: 1,041
Jul. 24, 2016 08:15 AM EDT Reads: 1,115
Jul. 24, 2016 08:00 AM EDT Reads: 717
Jul. 24, 2016 08:00 AM EDT Reads: 881
Jul. 24, 2016 08:00 AM EDT Reads: 2,273
Jul. 24, 2016 07:45 AM EDT Reads: 713
Jul. 24, 2016 07:30 AM EDT Reads: 756
Jul. 24, 2016 07:15 AM EDT Reads: 1,936
Jul. 24, 2016 07:00 AM EDT Reads: 1,412